Press releases
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
- Relmada Therapeutics Provides Corporate Update
Key statistics
On Thursday, Relmada Therapeutics Inc (4E2:MUN) closed at 4.32, -29.76% below its 52-week high of 6.15, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.32 |
---|---|
High | 4.32 |
Low | 4.32 |
Bid | 4.24 |
Offer | 4.38 |
Previous close | 4.40 |
Average volume | 111.11 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.69m |
P/E (TTM) | -- |
Market cap | 138.50m USD |
EPS (TTM) | -3.28 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼